Anna Luíza Soares de Oliveira Rodrigues, Lucas Carvalho Pereira, Thamiris Dias Delfino Cabral, Eric Pasqualotto, Isabela Fernandes Scabello, Mariele Pereira Bragante Rocha, Francisco Cezar Aquino de Moraes, Anna Luíza Damaceno Araújo, Luiz Paulo Kowalski
{"title":"超声引导下射频消融治疗原发性甲状旁腺功能亢进的疗效：系统综述和meta分析。","authors":"Anna Luíza Soares de Oliveira Rodrigues, Lucas Carvalho Pereira, Thamiris Dias Delfino Cabral, Eric Pasqualotto, Isabela Fernandes Scabello, Mariele Pereira Bragante Rocha, Francisco Cezar Aquino de Moraes, Anna Luíza Damaceno Araújo, Luiz Paulo Kowalski","doi":"10.1002/hed.28032","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiofrequency ablation guided by ultrasound (RFA-USG) is an alternative treatment for primary hyperparathyroidism (PHPT) patients. Despite showing accurate precision and minimal invasion, its efficacy remains questionable.</p><p><strong>Methods: </strong>We searched PubMed, Embase, Scopus, Cochrane Library, Portal Regional da Biblioteca Virtual em Saúde (BVS), Web of Science databases for randomized controlled trials (RCTs) and observational studies evaluating RFA-USG in PHPT patients. Statistical analysis was performed with R software, version 4.4.3.</p><p><strong>Results: </strong>Eight studies were included with 208 patients with PHPT undergoing RFA-USG treatment. After 3 months of treatment, parathyroid volume was 0.31 mL (0.16-0.61), Parathyroid hormone (PTH) level was 60.71 pg/mL (53.87-68.42), and calcium level was 5.43 mEq/L (2.63-11.23). The occurrence of hoarseness among the patients was 4.4% (1.64-11.02).</p><p><strong>Conclusion: </strong>RFA-USG is safe for PHPT patients, with associated parathyroid volume reduction and decrease in PTH. However, further study is needed to compare RFA-USG to the gold standard of surgery for PHPT.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Radiofrequency Ablation-Guided by Ultrasound in Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.\",\"authors\":\"Anna Luíza Soares de Oliveira Rodrigues, Lucas Carvalho Pereira, Thamiris Dias Delfino Cabral, Eric Pasqualotto, Isabela Fernandes Scabello, Mariele Pereira Bragante Rocha, Francisco Cezar Aquino de Moraes, Anna Luíza Damaceno Araújo, Luiz Paulo Kowalski\",\"doi\":\"10.1002/hed.28032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Radiofrequency ablation guided by ultrasound (RFA-USG) is an alternative treatment for primary hyperparathyroidism (PHPT) patients. Despite showing accurate precision and minimal invasion, its efficacy remains questionable.</p><p><strong>Methods: </strong>We searched PubMed, Embase, Scopus, Cochrane Library, Portal Regional da Biblioteca Virtual em Saúde (BVS), Web of Science databases for randomized controlled trials (RCTs) and observational studies evaluating RFA-USG in PHPT patients. Statistical analysis was performed with R software, version 4.4.3.</p><p><strong>Results: </strong>Eight studies were included with 208 patients with PHPT undergoing RFA-USG treatment. After 3 months of treatment, parathyroid volume was 0.31 mL (0.16-0.61), Parathyroid hormone (PTH) level was 60.71 pg/mL (53.87-68.42), and calcium level was 5.43 mEq/L (2.63-11.23). The occurrence of hoarseness among the patients was 4.4% (1.64-11.02).</p><p><strong>Conclusion: </strong>RFA-USG is safe for PHPT patients, with associated parathyroid volume reduction and decrease in PTH. However, further study is needed to compare RFA-USG to the gold standard of surgery for PHPT.</p>\",\"PeriodicalId\":55072,\"journal\":{\"name\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/hed.28032\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.28032","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：超声引导下射频消融（RFA-USG）是原发性甲状旁腺功能亢进（PHPT）患者的一种替代治疗方法。尽管显示出精确的精度和最小的入侵，但其有效性仍然值得怀疑。方法：检索PubMed、Embase、Scopus、Cochrane Library、Portal Regional da Biblioteca Virtual em Saúde （BVS）、Web of Science数据库，检索评估PHPT患者RFA-USG的随机对照试验（RCTs）和观察性研究。采用R软件4.4.3进行统计分析。结果：8项研究纳入208例接受RFA-USG治疗的PHPT患者。治疗3个月后，甲状旁腺体积0.31 mL(0.16 ~ 0.61)，甲状旁腺激素（PTH）水平60.71 pg/mL(53.87 ~ 68.42)，钙水平5.43 mEq/L（2.63 ~ 11.23）。患者声音嘶哑发生率为4.4%（1.64 ~ 11.02）。结论：RFA-USG用于PHPT患者是安全的，伴有甲状旁腺体积缩小和PTH下降。然而，RFA-USG与PHPT手术金标准的比较需要进一步的研究。
Efficacy of Radiofrequency Ablation-Guided by Ultrasound in Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.
Background: Radiofrequency ablation guided by ultrasound (RFA-USG) is an alternative treatment for primary hyperparathyroidism (PHPT) patients. Despite showing accurate precision and minimal invasion, its efficacy remains questionable.
Methods: We searched PubMed, Embase, Scopus, Cochrane Library, Portal Regional da Biblioteca Virtual em Saúde (BVS), Web of Science databases for randomized controlled trials (RCTs) and observational studies evaluating RFA-USG in PHPT patients. Statistical analysis was performed with R software, version 4.4.3.
Results: Eight studies were included with 208 patients with PHPT undergoing RFA-USG treatment. After 3 months of treatment, parathyroid volume was 0.31 mL (0.16-0.61), Parathyroid hormone (PTH) level was 60.71 pg/mL (53.87-68.42), and calcium level was 5.43 mEq/L (2.63-11.23). The occurrence of hoarseness among the patients was 4.4% (1.64-11.02).
Conclusion: RFA-USG is safe for PHPT patients, with associated parathyroid volume reduction and decrease in PTH. However, further study is needed to compare RFA-USG to the gold standard of surgery for PHPT.
期刊介绍：
Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
